Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Achilles Therapeutics PLC (ADR - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ACHL
Nasdaq
8731
https://www.achillestx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Achilles Therapeutics PLC (ADR
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?
- Jan 17th, 2023 2:40 pm
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Dec 20th, 2022 1:30 pm
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022
- Dec 6th, 2022 11:00 am
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022
- Nov 30th, 2022 11:05 pm
Achilles Therapeutics Announces Grant of US Patent on Immunotherapies Targeting Clonal Neoantigens Identified Using Proprietary Method
- Nov 22nd, 2022 1:00 pm
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?
- Nov 13th, 2022 12:48 pm
Achilles Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
- Nov 8th, 2022 12:00 pm
What Makes Achilles Therapeutics PLC Sponsored ADR (ACHL) a New Buy Stock
- Nov 1st, 2022 4:00 pm
Achilles Therapeutics Co-founder Professor Charles Swanton to Participate in Expert Roundtable Highlighting Pivotal Nature of Neoantigens as Targets in Cancer Cell Therapy
- Oct 6th, 2022 12:30 pm
Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication
- Sep 7th, 2022 5:15 pm
Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study
- Aug 31st, 2022 4:53 pm
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why
- Aug 26th, 2022 5:34 pm
AstraZeneca (AZN) Gets Japan Nod for Expanded Use of 3 Drugs
- Aug 25th, 2022 3:53 pm
Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study
- Aug 24th, 2022 5:33 pm
Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe
- Aug 23rd, 2022 5:53 pm
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
- Aug 19th, 2022 4:32 pm
Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914
- Aug 16th, 2022 2:09 pm
Achilles Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights
- Aug 9th, 2022 11:00 am
What Is The Ownership Structure Like For Achilles Therapeutics plc (NASDAQ:ACHL)?
- Aug 1st, 2022 10:00 am
Achilles Therapeutics to lead Horizon Europe-Funded Consortium to Advance Personalized Cell Therapy Manufacturing
- Jul 21st, 2022 12:00 pm
Scroll